ClinicalTrials.gg
CompletedNCT02765724Updated Mar 6, 2020

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

A Phase 1 interventional study of Pacritinib in Myelofibrosis, sponsored by CTI BioPharma. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Enrollment
11th of 18
28 · median 35
Started
2015
with 2 others
Phase 1
5 of 18
2 open now
Registered
8th of 18
by date
Lead sponsor
5 of 18
CTI BioPharma

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 11th largest by enrollment, is one of 3 that started in 2015, is one of 5 in phase 1, and was the 8th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This is an open-label, parallel-group, single-dose study of the PK and safety of 400 mg pacritinib administered orally to patients with stable chronic liver disease and healthy control subjects.

Read the detailed description

All study participants will undergo screening evaluations to determine eligibility for the study. All screening evaluations must be performed within 28 days of pacritinib dosing (Day 1). Assignment of patients to each hepatic impairment group will be defined by Child-Pugh Clinical Assessment Score at the time of Screening. Group 3 patients will not be dosed until at least 2 patients combined from Groups 1 and 2 have completed the study (Day 8). Healthy subjects will be enrolled after hepatic impairment accrual is complete to allow for age-, gender- and body mass index- (BMI) matching with the hepatic impairment population. Participants will be admitted to the study site on Day -1 (i.e., Check-in). On Day 1, upon receipt of all baseline safety evaluation results and confirmation of eligibility, study participants will be administered a single dose of 400 mg pacritinib orally under fasting conditions. Fasting will start 10 hours prior to pacritinib administration and continue for an additional 4 hours after administration. Following administration of pacritinib, participants will remain confined to the study site for 168 hours (8 days) after pacritinib dosing for collection of blood for PK and safety assessments.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Study Participants

  1. Male and/or female from 18-85 years of age, inclusive
  2. Must be in sufficiently good health to tolerate the study treatment and procedures and be evaluable for possible effects of hepatic dysfunction on pacritinib PK without significant confounding issues, in the opinion of the investigator in consultation with the Sponsor
  3. Must be using a medically-approved method

    • Females must be non-pregnant and non-lactating, and females not of must be for at least 1 year or surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days, or agree to use, from the time of signing the or 10 days prior to Check-in (Day -1) until 30 days after Study Completion (Day 8)/Early Termination, one of the following forms of contraception: non-hormonal intrauterine device (IUD) with spermicide; female condom with spermicide; contraceptive sponge with spermicide; intravaginal system (e.g., NuvaRing®); diaphragm with spermicide; cervical cap with spermicide; male sexual partner who agrees to use a male condom with spermicide; sterile sexual partner; or abstinence. Oral, implantable, transdermal, or injectable contraceptives may not be used from the time of signing the informed consent or 10 days prior to Check-in (Day -1) until 14 days after the final dose administration. For all females, the pregnancy test result must be negative at Screening and Check-in (Day -1)
    • Males will be sterile, or completely abstain from sexual intercourse, or agree to use, from Check-in (Day -1) until 90 days following Study Completion/ET, one of the following approved methods of contraception: male condom with spermicide; sterile sexual partner; or use by female sexual partner of an IUD with spermicide; a female condom with spermicide; a contraceptive sponge with spermicide; an intravaginal system; a diaphragm with spermicide; a cervical cap with spermicide; or oral, implantable, transdermal, or injectable contraceptives. Study participants will refrain from sperm donation from Check-in (Day -1) until 90 days following Study Completion (Day 8)
  4. between 18-40 kg/m2 (inclusive) at Screening
  5. Vital signs (after 3 minutes seated position rest then measured in the seated position) within the following ranges, inclusive, unless deemed not by the Investigator, as approved by the Sponsor:

    • oral body temperature between 35.0-37.5 °C
    • systolic blood pressure, 90-160 mm Hg
    • diastolic blood pressure, 50-100 mm Hg
    • pulse rate, 50-100 bpm

    Blood pressure and pulse will be taken again in a standing position. After 3 minutes standing, there shall be no more than a 20 mm Hg drop in systolic blood pressure associated with symptomatic postural hypotension

  6. Negative test for selected drugs of abuse (including alcohol) at Screening and at Baseline, prior to admission to study site, except for positive tests due to prescribed drugs in hepatic impaired patients
  7. Negative (HIV) antibody screens
  8. Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent. Legal authorized representatives are not permitted

    Patients with Hepatic Impairment Only

  9. Clinical Assessment Score consistent with degree of hepatic impairment that is not attributable to any other underlying disease
  10. Patients assigned to a hepatic impairment group must be evaluable and meet criteria for hepatic impairment per the Child-Pugh Clinical Assessment Score

    Healthy subjects only

  11. Healthy subjects will be identified after all hepatic impairment patients have been enrolled and the healthy subject group will have similar distributions of age (by hepatic impairment population quartiles), BMI (by hepatic impairment population quartiles) and gender
  12. Negative hepatitis panel (including surface antigen [HBsAg], hepatitis B core antibody (anti-HBc), and virus antibody [anti-HCV])

Exclusion criteria

Exclusion Criteria:

Study participants meeting any of the following criteria during Screening or Baseline evaluations will be excluded from entry into or continuation in the study:

All Study Participants

  1. Participation in any clinical investigation within 4 weeks prior to Check-in or longer if required by local regulation
  2. Participation in any clinical investigation involving receipt of study drug within 5 half-lives or 30 days prior to Check-in (Day -1) (whichever is longer)
  3. Donation or loss of 400 mL or more of blood within 8 weeks prior to Check-in
  4. Significant illness within the two weeks prior to Check-in
  5. A past medical history of abnormalities, presence of an abnormal ECG (which in the Investigator's opinion is clinically significant), >450 msec, or has concomitant conditions that significantly increase risk for QTc interval prolongation such as heart failure or family history of long QT interval syndrome)
  6. Resting heart rate \< 50 beats per minute (bpm)
  7. Alcohol ingestion within 72 hours of Check-in
  8. Urine Cotinine levels ≥ 150 ng/mL
  9. Use of potent inducers of (Appendix 4) within 30 days of Check-in
  10. Use of potent inhibitors of CYP3A4 (Appendix 4) within 15 days of Check-in
  11. Use of over-the-counter medications (except as prescribed by a physician), vitamins, or phytotherapeutic/herbal/plant-derived preparations within 14 days of Check-in
  12. Consumption of grapefruit- and grapefruit-containing products is not permitted within 7 days of Check-in
  13. History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known to the study drug, study drug , or drugs similar to the study drug
  14. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the study participant in case of participation in the study. The investigator should be guided by evidence of any of the following:

    • history of inflammatory bowel syndrome
    • recent history (within 1 year) of ongoing gastritis or ulcers
    • history of major gastrointestinal tract surgery such as gastrectomy, gastroentero- stomy, or bowel resection (esophageal varix surgery is allowable)
    • clinical evidence of pancreatic injury or pancreatitis
    • evidence of urinary obstruction or difficulty in voiding at Screening
  15. History of immunocompromise, including a positive test result

    Patients with Hepatic Impairment Only

  16. Clinically significant abnormal findings in physical examination, ECG or laboratory evaluations not consistent with known clinical disease
  17. Symptoms or history of Stage II or worse degree of encephalopathy within 6 months of study entry as judged by the investigator
  18. Clinical evidence of severe ascites: ascites causing marked abdominal distension and/or being to medical therapy
  19. History of surgical portosystemic shunt
  20. \<1500/mm3, count \<30,000/mm3, \<9 g/dL
  21. > 18 seconds
  22. (CrCl) of less than 60 ml/min as calculated by the Cockcroft-Gault equation ((140-age in years) × (Weight in kg) × (0.85 if female) / (72 × Serum Creatinine in mg/dL))
  23. Any evidence of progressive liver disease (as available within the last 4 weeks, including the time period between Screening and Check-in) as indicated by liver transaminases, alkaline phosphatase, and gamma-glutamyl transpeptidase or a ≥ 50% worsening of serum or prothrombin time
  24. Urinalysis with any result outside the normal range and deemed clinically significant. Results deemed not clinically significant by investigator in consultation with the Sponsor are allowable
  25. Initiation of any otherwise allowable prescription or over-the-counter medications within 15 days of Check-in. Some of these medications may have to be discontinued 12 to 48 hours pre-dose, or earlier. As medication regimens vary and cannot be predicted, each patient shall be discussed with the Sponsor individually
  26. History of drug or alcohol abuse within the last 3 months, or evidence of recent drug or alcohol abuse in alcohol test and drug screen conducted during Screening or Baseline evaluations

    Healthy Subjects Only

  27. Any Screening or Baseline laboratories outside the normal range and deemed clinically significant. Results outside the normal range and deemed not clinically significant by investigator, in consultation with the Sponsor, are allowable
  28. History of drug or alcohol abuse within the last 12 months, or evidence of such abuse as indicated by the laboratory assays conducted during the Screening or Baseline evaluations
  29. Use of any prescription medication within 1 month prior to Check-in
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Group 1

    Patients with mild hepatic impairment

    Drug: Pacritinib

  • Experimental
    Group 2

    Patients with moderate hepatic impairment

    Drug: Pacritinib

  • Experimental
    Group 3

    Patients with severe hepatic impairment

    Drug: Pacritinib

  • Experimental
    Group 4

    Healthy subjects

    Drug: Pacritinib

Interventions

  • Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration

    Also known as: Pacritinib 400mg capsule

06

What researchers measure

Primary outcomes

  1. To characterize the pharmacokinetic profile of a single 400-mg dose of pacritinib and its major metabolites in patients with hepatic impairment as compared to gender-, age-, and body mass index -matched healthy subjects with normal liver function

    Plasma concentrations of pacritinib and any major metabolites were determined by a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric assay. The lower limit of quantitation of the assay is 20 ng/mL for pacritinib and 4 ng/mL for PAC-M1 metabolite in plasma

    Time frame: Plasma: 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose

Secondary outcomes

  1. To evaluate the safety of pacritinib and tolerability of a single 400-mg dose of pacritinib in patients with hepatic impairment and healthy subjects;

    Adverse events, vital signs, physical examinations, clinical laboratory valuations, and ECGs

    Time frame: 00:00 of ICF signature until 1 min before IP admin and from the date-time of IP administration until 23:59 of the day of last contact

07

Study locations

2 sites
  • APEX GmbH
    Munich, D-81241, Germany
  • Republican Clinical Hospital
    Chisinau, MD-2025, Moldova, Republic of
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
May 9, 2016
Start
Jan 2015
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Last update
Mar 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02765724
Lead sponsor
CTI BioPharma
Collaborators
SGS S.A.
Responsible party
Sponsor
First posted
May 9, 2016
Start date
Jan 2015
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Mar 6, 2020

Study contacts

James Dean, MD, PhD
study director · CTI BioPharma
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion